Departments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology, Worm Institute of Research and Medicine (WIRM), Scripps Research, 10550 N Torrey Pines Road, La Jolla, CA 92037, United States.
Center for Biopharmaceuticals & Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, University of Copenhagen, Universitetsparken 2, DK-2100, Copenhagen, Denmark.
Toxicon. 2021 Jan;190(Suupl 1):S72-S73. Epub 2021 Jan 16.
Botulinum neurotoxin A (BoNT/A) is extremely toxic possessing an estimated intravenous LD of 1-2 ng/kg and as such has been designated a category A bioterrorism agent. BoNT/A also possesses an extremely long half-life and persists within muscle neurons for months to >1 year. Because of BoNT/A longevity, we have utilized covalent inhibition as a means to abrogate BoNT/A's toxicity. To this end, we describe an approach to designing inhibitors that possess both electrophilic warheads and metal-binding groups for the bifunctional inhibition of BoNT/A.
Small molecule inhibitors that possessed electrophilic moieties were designed, using X-ray crystallography as guidance, to target both the zinc metal-binding region and Cys165 within the active site of BoNT/A. Synthesized compounds were evaluated for covalent inhibition using a continuous SNAPtide FRET assay and exhaustive dialysis. Compounds were also evaluated against a C165A variant. Compound reactivity, stability, MMP selectivity and cellular efficacy/toxicity was also evaluated.
Several electrophilic warhead types were confirmed to inhibit BoNT/A LC covalently with substantial differences in time-dependent inhibition between the WT and C165A variant. A trend in warhead reactivity was reflected in inhibitor stability and toxicity. Compounds exhibited moderate potency in a BoNT/A neuronal cellular assay but were not further explored due to undesirable therapeutic potential.
A fundamental framework for the bifunctional covalent inhibition of BoNT/A LC has been established. This approach has potential to be translated to other small molecule metal-binding inhibitors of BoNT/A LC with the vision that different pharmacophores, possessing improved physicochemical properties, will address BoNT/As toxicity and longevity within cells.
肉毒神经毒素 A(BoNT/A)具有极高的毒性,其静脉注射的半数致死量估计为 1-2ng/kg,因此被列为 A 类生物恐怖制剂。BoNT/A 还具有极其长的半衰期,并在肌肉神经元中持续存在数月至>1 年。由于 BoNT/A 的半衰期长,我们利用共价抑制作为一种消除 BoNT/A 毒性的方法。为此,我们描述了一种设计具有亲电弹头和金属结合基团的抑制剂的方法,用于双功能抑制 BoNT/A。
使用 X 射线晶体学作为指导,设计了具有亲电部分的小分子抑制剂,以靶向 BoNT/A 的锌金属结合区域和活性位点中的 Cys165。使用连续 SNAPtide FRET 测定和彻底透析法评估合成化合物的共价抑制作用。还评估了这些化合物对 C165A 变体的抑制作用。还评估了化合物的反应性、稳定性、MMP 选择性和细胞功效/毒性。
几种亲电弹头类型被证实能以共价方式抑制 BoNT/A LC,WT 和 C165A 变体之间的时间依赖性抑制有很大差异。弹头反应性的趋势反映在抑制剂的稳定性和毒性上。化合物在 BoNT/A 神经元细胞测定中表现出中等效力,但由于不理想的治疗潜力,没有进一步探索。
已经建立了 BoNT/A LC 双功能共价抑制的基本框架。这种方法有可能转化为其他 BoNT/A LC 的小分子金属结合抑制剂,其设想是具有改进的物理化学性质的不同药效团将解决 BoNT/A 的毒性和细胞内的半衰期。